Skip to main content

Table 2 Frequency of Use of Anti-Diabetic Medications

From: Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression

Anti-Diabetic Medications Diabetes (N = 55.972) Diabetic Neuropathy (N = 2,146) Diabetes and Depression (N = 2,379) P-Value
  N % N % N % DM v DN DM v DD DN v DD
Sulfonylurea          
   Glimepiried 2,821 5.04 180 8.29 192 8.07 * * 0.8823
   Glipizide 9,034 16.14 458 21.34 554 23.29 * * 0.1846
   Glyburide 7,446 13.30 451 21.02 466 19.59 * * 0.3454
   Any Sulfonylurea 18,207 32.53 924 43.06 1,072 45.06 * * 0.3253
Meglitinide          
   Nateglinide 222 0.40 19 0.89 6 0.25 *** 0.5252 ***
   Repaglinide 863 1.54 63 2.94 1 2.27 * *** 0.1790
   Any Meglitinide 1,078 1.93 82 3.32 60 2.52 * 0.1059 ***
Biguanide          
   Metformin HCL 15,744 28.13 952 44.36 1,072 45.06 * * 0.8625
Thiazolidinedione          
   Pioglitazone HCL 2,371 4.24 227 10.58 233 9.79 * * 0.4238
   Rosiglitazone Maleate 3,073 5.49 287 13.37 292 12.27 * * 0.2650
   Any Thiazolidinedione 5,283 9.44 491 22.88 494 20.77 * * ***
Alpha Glucose Inhibitor          
   Acarbose 256 0.46 13 0.61 18 0.76 0.5883 0.0939 0.7412
   Miglitol 112 0.20 13 0.61 1 0.04 ** 0.2222 *
   Any Alpha Glucose Inhibitor 363 0.65 26 1.21 19 0.80 *** 0.6553 0.2072
Insulin          
   Insulin Glargine 272 0.49 68 3.17 75 3.15 * * 0.9976
   Insulin Lispro 2,837 5.07 469 21.85 359 15.09 * * *
   Any Insulin 2,940 5.25 493 22.97 381 16.02 * * *
  1. *P-value ≤ 0.0001; **P-value ≤ 0.001; ***P-value ≤ 0.05.
  2. P values based on Tukey-Kramer method to adjust for multiple comparisons.